Systematic review of neoadjuvant therapy by Immune checkpoint inhibitors before radical cystectomy: where do we stand?

CONCLUSIONS: Pembrolizumab and Atezolizumab single-agent demonstrated favorable results for ICI in the neoadjuant setting. Patients with a higher tumor expression of PD-1 and PD-L1 appear to experience a higher response to ICI, although the adequate biomarker remains to be identified. Radical cystectomy appears to be safe after ICI treatment. The results of the currently ongoing prospective trial are awaited with impatience by the urooncologic community. PMID: 32993274 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research